Rani Therapeutics Holdings, Inc.(RANI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Rani Therapeutics Holdings, Inc. (RANI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RANI at 28.5/100 on a 32-signal composite quality model, placing it at rank #2,555 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Rani Therapeutics Holdings, Inc. reports quarterly revenue of $1.7M, net income of $-7.4M, free cash flow of $-9.1M. Top institutional holders of RANI by reported 13-F value include Samsara BioCapital, RA CAPITAL MANAGEMENT, L.P., AWM Investment Company, based on the most recent SEC filings. RANI trades on the Nasdaq exchange and files with the SEC under CIK 1856725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RANI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rani Therapeutics Holdings, Inc. directly from SEC EDGAR.